Efficacy and Safety of Ningmitai Capsules in Patients with Chronic Epididymitis: A Prospective, Parallel Randomized Controlled Clinical Trial

Objectives To evaluate the efficacy and safety of Ningmitai (NMT) capsules in patients with chronic epididymitis. Methods This prospective randomized controlled trial included 112 patients diagnosed with chronic epididymitis. The patients were randomized (1 : 1 : 1) to receive levofloxacin (LVX), NMT, or NMT combined with LVX for 4 weeks. The patients were followed up at 2 and 4 weeks after initiation of treatment and were evaluated in terms of Chronic Epididymitis Symptom Index (CESI) scores, epididymal nodules, and safety parameters. The primary endpoints were the CESI scores at the end of 2 and 4 weeks of treatment. The secondary endpoints included the mean epididymal nodule diameter and the clinical efficacy rate. Safety was evaluated by hepatorenal function tests and adverse event reports during the trial. Results After 2 weeks of treatment, the CESI score of the NMT group was significantly lower than that of the LVX group (P < 0.05). In addition, the clinical efficacy rate of the NMT group was significantly higher than that of the LVX group (55% vs. 8.33%, P < 0.0001), indicating that NMT has a rapid effect on chronic epididymitis. After 4 weeks of treatment, there was no significant difference in CESI scores or clinical efficacy rates between the two monotherapy regimens (P > 0.05); however, the mean diameter of epididymal nodules was significantly smaller in the NMT group than in the LVX group (P < 0.0001). Moreover, after 4 weeks of treatment, the patients in the LVX + NMT group, which had a clinical efficacy rate of 97.22%, had lower CESI scores (both P < 0.01) and a smaller epididymal nodule diameter (vs. LVX, P < 0.0001; vs. NMT, P < 0.05) than those in the other two groups. No adverse events or abnormal hepatorenal function were found during the study. Conclusion NMT significantly improved CESI scores and epididymal nodule diameter in patients with chronic epididymitis. The combination of NMT and LVX provides a much better effect than monotherapy, and this treatment regimen was well tolerated.

[1]  W. Bai,et al.  Efficacy and Safety of Ningmitai Capsule in Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. , 2021, Urology.

[2]  Yudan Liang,et al.  Efficacy of Bloodletting Therapy in Patients with Chronic Idiopathic Urticaria: A Randomized Control Trial , 2020, Evidence-based complementary and alternative medicine : eCAM.

[3]  Young Il Kim,et al.  Gyejigachulbutang (Gui-Zhi-Jia-Shu-Fu-Tang, Keishikajutsubuto, TJ-18) in Degenerative Knee Osteoarthritis Patients: Lessons and Responders from a Multicenter Randomized Placebo-Controlled Double-Blind Clinical Trial , 2020, Evidence-based complementary and alternative medicine : eCAM.

[4]  Abdullah M. Asiri,et al.  Recent developments of gallic acid derivatives and their hybrids in medicinal chemistry: A review. , 2020, European journal of medicinal chemistry.

[5]  Chi Zhang,et al.  The Anti-Inflammatory and Antioxidative Effects of Ningmitai Capsule in the Experimental Autoimmune Prostatitis Rat Model , 2020, Evidence-based complementary and alternative medicine : eCAM.

[6]  Huanyuan Wang,et al.  Effects of Acupuncture on Hospitalized Patients with Urinary Retention , 2020, Evidence-based complementary and alternative medicine : eCAM.

[7]  S. M. Borghi,et al.  The granulopoietic cytokine granulocyte colony-stimulating factor (G-CSF) induces pain: analgesia by rutin , 2019, Inflammopharmacology.

[8]  Zhong Chen,et al.  Meta-analysis of the efficacy of Ningmitai capsule on the treatment of chronic prostatitis in China , 2018, Medicine.

[9]  B. Shi,et al.  Quercetin protects against chronic prostatitis in rat model through NF‐κB and MAPK signaling pathways , 2018, The Prostate.

[10]  M. H. Hashempur,et al.  A comparative study of ranitidine and quince (Cydonia oblonga mill) sauce on gastroesophageal reflux disease (GERD) in pregnancy: a randomised, open-label, active-controlled clinical trial , 2018, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[11]  M. H. Hashempur,et al.  Effects of rhubarb (Rheum ribes L.) syrup on dysenteric diarrhea in children: a randomized, double-blind, placebo-controlled trial. , 2017, Journal of integrative medicine.

[12]  F. Aiello,et al.  Quercetin and derivatives: useful tools in inflammation and pain management. , 2017, Future medicinal chemistry.

[13]  J. McConaghy,et al.  Epididymitis: An Overview. , 2016, American family physician.

[14]  R. Peixoto,et al.  Epididymitis following Cytoreductive Surgery with Intraperitoneal Oxaliplatin Chemotherapy: Two Case Reports , 2016, Case Reports in Oncology.

[15]  Y. Teng,et al.  Luteolin decreases the attachment, invasion and cytotoxicity of UPEC in bladder epithelial cells and inhibits UPEC biofilm formation. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[16]  J. Chung,et al.  Inhibition of adhesion and fibrosis improves the outcome of epididymectomy as a treatment for chronic epididymitis: a multicenter, randomized controlled, single-blind study. , 2013, The Journal of urology.

[17]  T. Sulser,et al.  Chronic scrotal pain syndrome (CSPS): the widespread use of antibiotics is not justified , 2008, Andrology.

[18]  J. Teichman,et al.  Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: the Canadian PIE Study. , 2005, Urology.

[19]  J. Nickel.  Chronic epididymitis: a practical approach to understanding and managing a difficult urologic enigma. , 2003, Reviews in urology.

[20]  Z. Kırkalı,et al.  Re: The patient with chronic epididymitis: characterization of an enigmatic syndrome. , 2002, The Journal of urology.